BioPharma Resources

Drug Trial Radar · NCT01456936

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

A Phase 4, Randomized, Double-blind, Active And Placebo-controlled, Multicenter Study Evaluating The Neuropsychiatric Safety And Efficacy Of 12 Weeks Varenicline Tartrate 1mg Bid And Bupropion Hydrochloride 150mg Bid For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

Last checked: Nov 19, 2026Latest source record: Jun 10, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 8,144 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8,144

Actual

Start

Nov 2011

Primary completion

Jan 2015

Study completion Jan 2015

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Oct 21, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is being conducted to assess varenicline and bupropion as aids to smoking cessation treatment in subjects with and without an established diagnosis of major psychiatric disorder and to characterize the neuropsychiatric safety profile (pre-specified adverse events (AEs) in both of these populations).

Conditions

  • Smoking Cessation

Interventions

  • PlaceboDrug

    Triple dummy placebo for each treatment arm

  • varenicline tartrateDrug

    Subjects will be titrated to the full dose during the first week in the following manner: 0.5 mg (tablet form) once a day for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 11 weeks

  • bupropion hydrochlorideDrug

    Subjects will receive 150 mg (tablet form) once a day for 3 days and then will take 150 mg twice a day for the remainder of the treatment period (11 weeks and 4 days).

  • Nicotine Replacement Therapy PatchDrug

    Subjects will start active dosing the morning of the Week 1 visit and will receive a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Neuropsychiatric (NPS) Adverse Events (AE) - the Primary Study EndpointTime frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
  2. Estimated NPS AE Rate (%), by CohortTime frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

Locations

156 sites in 16 countries. Site status is shown where the registry gives one.

  • Coastal Clinical Research, Inc.

    Mobile, Alabama

  • NoesisPharma Research

    Phoenix, Arizona

  • Pharmacology Research Institute

    Encino, California

  • Synergy Clinical Research of Escondido

    Escondido, California

  • Sun Valley Research Center

    Imperial, California

  • Omega Clinical Trials

    La Habra, California

  • Pacific Treatment and Research Center UC San Diego Health System

    La Jolla, California

  • Pharmacology Research Institute

    Los Alamitos, California

  • David Geffen School of Medicine at University of California, Los Angeles

    Los Angeles, California

  • Pharmacology Research Institute

    Newport Beach, California

  • North County Clinical Research

    Oceanside, California

  • Neuropsychiatric Research Center of Orange County

    Orange, California

  • California Neuroscience Research Medical Group, Inc.

    Sherman Oaks, California

  • University of Colorado Denver, Anschutz Medical Campus , Behavioral Health and Wellness Program

    Aurora, Colorado

  • Western Affiliated Research Institute

    Denver, Colorado

  • Comprehensive Psychiatric Care

    Norwich, Connecticut

  • Neuropsychiatric Research Center of Southwest Florida

    Fort Myers, Florida

  • Broward Research Group

    Hollywood, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Mayo Clinic

    Jacksonville, Florida

  • Clinical Neuroscience Solutions,Inc.

    Jacksonville, Florida

  • Meridien Research

    Lakeland, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Ocala Psychiatric Associates

    Ocala, Florida

  • Clinical Neuroscience Solutions, Inc

    Orlando, Florida

  • Meridien Research

    Tampa, Florida

  • Northwest Behavioral Research Center

    Marietta, Georgia

  • Clinical Research Atlanta

    Stockbridge, Georgia

  • Advanced Clinical Research

    Meridian, Idaho

  • Northwest Neurobehavioral Health

    Meridian, Idaho

  • AMR-Baber Research Inc.

    Naperville, Illinois

  • American Health Network of IN, LLC

    Indianaopolis, Indiana

  • Davis Clinic, Incorporated

    Indianapolis, Indiana

  • Goldpoint Clinical Research, LLC

    Indianapolis, Indiana

  • Vince and Associates Clinical Research

    Overland Park, Kansas

  • Heartland Research Associates, LLC

    Wichita, Kansas

  • Central Kentucky Research Associates, Inc.

    Lexington, Kentucky

  • Kentucky Research Group

    Louisville, Kentucky

  • A Professional Corporation dba The Center for Sexual Health

    Metairie, Louisiana

  • Maine Research Associates

    Auburn, Maine

Showing 40 of 156 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.